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INTRODUCTION
Chronic graft-versus-host disease (GVHD) is an impor-
tant cause of late transplantation-related mortality and
morbidity after allogeneic hematopoietic stem cell trans-
plantation (HSCT) [1-4]. Risk factors for the development
of this complication include increasing patient and donor
age, HLA disparity, GVHD prophylaxis with cortico-
steroids, preceding acute GVHD, viable donor buffy coat
infusions posttransplantation, and the use of corticosteroids
at day 100 [1,5,6]. Among long-term survivors, the incidence
of chronic GVHD varies between 33% after transplantation
from HLA-identical related siblings to 64% after matched
unrelated transplantation [1]. The prevalence of this com-
plication is predicted to increase worldwide, considering the
growing number of allogeneic HSCTs performed annually
[7]. The most prominent prognostic factors for poor out-
come are a progressive onset from acute GVHD, concomi-
tant thrombocytopenia, and multiorgan involvement [1,3].
The combination of cyclosporine and corticosteroids is con-
sidered the standard of therapy for primary treatment of
chronic GVHD in many transplantation centers. However,
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ABSTRACT
Chronic graft-versus-host disease (GVHD) is the principal cause of transplantation-related morbidity and nonre-
lapse mortality late after allogeneic hematopoietic stem cell transplantation. The safety and potential efficacy of
tacrolimus for the salvage treatment of chronic GVHD was evaluated in a single-arm, open-label phase 2 study. A
total of 39 evaluable patients with chronic GVHD who failed previous immunosuppressive therapy with cyclo-
sporine and prednisone were treated with tacrolimus starting at a median of 20 months (range, 3-68 months) after
transplantation. At 3 years after the start of treatment, 5 patients (13%) had discontinued tacrolimus and were in
complete remission, and 3 were considered clinically stable but not able to discontinue tacrolimus. A total of
31 patients (79%) experienced treatment failure; 22 (56%) who failed therapy had a change in immunosuppressive
regimen because of progression (n = 18) or toxicity (n = 4). Nine patients (23%) died during continued treatment
with tacrolimus. Two patients were lost to follow-up, at 11 and 19 months. The median duration of treatment with
tacrolimus was 9 months (range, 1-29 months). Infections (144 episodes) were the most frequent adverse event.
Nephrotoxicity occurred in 16 patients (41%); tacrolimus was discontinued in only 2 patients because of progres-
sive deterioration in renal function. The Kaplan-Meier estimate of survival was 64% (95% confidence interval,
49%-79%) at 3 years posttransplantation. Seven patients had discontinued all immunosuppression at last contact,
leading to an estimated 29% probability of stopping all immunosuppression by 3 years posttransplantation. Four
patients died after relapse of malignancy. The response rate is consistent with previous reports of salvage treat-
ment for chronic GVHD, indicating that a small group of patients failing cyclosporine may respond or stabilize
with tacrolimus.
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in many patients, chronic GVHD may be refractory to this
combination, and progression of disease occurs [1,3,4,8].
In solid organ transplantation, tacrolimus is more effec-
tive than cyclosporine in the treatment and prevention of
allograft rejection [9-16]. Preclinical studies showed that
after bone marrow transplantation, tacrolimus prevented
and controlled GVHD in rats and dogs [17-19]. In the rat
model, tacrolimus as a single agent protected the marrow
recipients from acute GVHD for a longer period than
cyclosporine. In the canine model, the combination of
tacrolimus with methotrexate (MTX) was more effective
than tacrolimus alone. Clinically, several phase 2 studies
have established that tacrolimus was well tolerated and
effective for GVHD prophylaxis [20-22].
Recently, three phase 3 studies demonstrated that the
combination of tacrolimus and short-course MTX decreased
the probability of acute GVHD compared with cyclosporine
and MTX in both related and unrelated transplants [23-25].
Based on the hypothesis that replacing cyclosporine with
tacrolimus may result in improved control of chronic
GVHD, we conducted a phase 2 study of tacrolimus as sal-
vage therapy for patients failing initial treatment.
PATIENTS AND METHODS
Patients
Between June 1995 and December 1997, 40 patients
with extensive chronic GVHD were enrolled at the Fred
Hutchinson Cancer Research Center (Seattle, WA) to
receive salvage treatment with tacrolimus after failing pri-
mary treatment. Protocol and consent forms were approved
by the Institutional Review Board at the Fred Hutchinson
Cancer Research Center.
Patient characteristics are described in Table 1. All eligible
patients, except 3 who received peripheral blood stem cells,
received a bone marrow transplantation after a high-dose con-
ditioning regimen for hematologic malignancies [26].
Three patients had previous allogeneic (n = 2) or autol-
ogous (n = 1) transplantations. The time to chronic
GVHD and to the start of salvage treatment were deter-
mined from the date of the last transplantation. Acute
GVHD prophylaxis varied over time according to active
institutional protocols [23,24,27].
Assessment and Treatment of Chronic GVHD
Chronic GVHD was considered to have a progressive
onset in patients without an interval of remission from acute
GVHD. Quiescent onset was defined as the occurrence of
chronic GVHD after a period of remission from acute
GVHD. De novo chronic GVHD was not preceded by
acute GVHD. The diagnosis of chronic GVHD was estab-
lished at the time of the ﬁrst-line treatment on the basis of
clinical, laboratory, and hematologic data by previously pub-
lished criteria [28]. The standard treatment for chronic
GVHD was to treat patients who received transplants from
related donors with cyclosporine and prednisone every
other day [8] and patients who received transplants from
unrelated donors with cyclosporine daily and prednisone
every other day (Table 2). Patients were eligible for the
study if first-line therapy had failed to control chronic
GVHD. Failure of first-line therapy was defined as no
improvement of chronic GVHD after 3 months of previous
treatment or as a progression of chronic GVHD after 6 to
8 weeks. After failure of ﬁrst-line therapy, cyclosporine was
stopped, and tacrolimus was started 12 hours after the last
cyclosporine dose. Tacrolimus was started at an oral dosage
of 0.12 mg/kg per day based on ideal body weight. If intra-
venous infusion was required, the dose was converted from
the oral formulation at a 1:4 ratio. During the study period,
tacrolimus whole-blood trough levels were maintained
between 10 and 30 ng/mL. Blood levels were assessed by
IMX after the first and second week and at least every
Table 1. Characteristics of Patients With Chronic GVHD Enrolled at the Fred
Hutchinson Cancer Research Center Between June 1995 and December 1997*
Registered patients 40
Diagnosis
Chronic myelogenous leukemia 13 (32)
Acute nonlymphoblastic leukemia 12 (30)
Myelodysplastic syndrome 7 (17)
Acute lymphoblastic leukemia 4 (10)
Non-Hodgkin’s lymphoma 2 (5)
Hodgkin’s disease 1 (3)
Chronic lymphocytic leukemia 1 (3)
Age of patients, y 37 (4-44)
Age distribution, y
<12 4 (10)
12-30 9 (23)
>30 27 (67)
Histocompatibility
Related 25 (63)
HLA-matched 19 (47)
1 antigen mismatched 3 (8)
2 antigen mismatched 3 (8)
Unrelated 15 (37)
HLA-matched 11 (27)
1 antigen mismatched 4 (10)
Sex
Male 21 (53)
Female 19 (47)
Conditioning regimens
CY/TBI 22 (55)
BU/CY 8 (20)
BU-containing 5 (12)
CY/TBI/ATG 2 (5)
BCNU/CY/TBI 1 (2)
BCNU/CY/VP-16 1 (2)
BC3/PDN 1 (2)
Acute GVHD prophylaxis
CSP/MTX 27 (67)
CSP/MTX/ATG 3 (8)
CSP 6 (15)
MTX/tacrolimus† 2 (5)
CSP/corticosteroids 2 (5)
*Data are n, n (%), or median (range). CY indicates cyclophos-
phamide; TBI, total body irradiation; BU, busulfan; ATG, antithymo-
cyte globulin; BCNU, carmustine; BC3, CD3-specific monoclonal
antibody; PDN, prednisone; GVHD, graft-versus-host disease; CSP,
cyclosporine; MTX, methotrexate.
†These 2 patients developed quiescent chronic GVHD after
tacrolimus discontinuation and were treated for chronic GVHD with
CSP/corticosteroids according to center policy.
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3 months if clinically indicated. Prednisone was given at a
dosage of 1 mg/kg QOD along with tacrolimus. If a patient
achieved a response, a 25% dose reduction for prednisone
and tacrolimus was planned at weeks 21 and 22, respectively.
Thereafter, if the patient maintained the response, a slow
taper of immunosuppressive therapy was generated with
tacrolimus as the last agent to be discontinued.
Supportive Care
Patients received trimethoprine/sulfamethoxazol (TMP/
SMX) for Pneumocystis carinii prophylaxis. According to
standard treatment policy, adult patients received 1 double-
strength (160 mg TMP) tablet BID, 2 days per week, and
daily penicillin or daily TMP/SMX without penicillin; chil-
dren received TMP/SMX alone at 45 mg/m2 twice per day.
Supportive care also included artiﬁcial tear replacement, a
sun-blocking agent, and nutritional supplementation.
Response Evaluation
Responses were evaluated at 9 to 12, 18 to 24, and 27 to
36 months from the start of tacrolimus treatment.
Responses were also evaluated at the last recorded value
before death. Patients were encouraged to have reevaluation
in Seattle at each anniversary after transplantation or at
other times when clinically indicated. If a patient could not
return to Seattle for the yearly reevaluation, a questionnaire
about recent medical history, medications, and quality of life
was sent to the referring physician. At reevaluation, patients
had a physical examination, assessment of Karnofsky perfor-
mance score, laboratory studies, pulmonary function tests
(at 1-year HSCT anniversary and if clinically indicated),
Schirmer’s test, assessment of nutritional status, and a rou-
tine skin biopsy (as well as other biopsies if clinically indi-
cated, as previously described [6]).
The categories of outcome were established based on
need for immunosuppressive therapy and clinical status. The
categories were as follows: (1) treatment success—patients
who had a complete response of chronic GVHD and had dis-
continued tacrolimus therapy, (2) clinically stable—patients
with stable disease and continuing treatment with tacrolimus,
and (3) treatment failure—patients who either discontinued
tacrolimus treatment because of progression/persistence of
chronic GVHD or toxicity of tacrolimus and required addi-
tional immunosuppressive therapy or patients who died dur-
ing treatment with tacrolimus. Complete response (CR) was
deﬁned as clinically inactive disease, a Karnofsky performance
status of >70, and discontinuation of tacrolimus. Patients with
persistent ocular sicca syndrome but otherwise complete
response in all other organs were considered to be complete
responders. Clinically stable patients were improved but may
have had evidence of active chronic GVHD in some organs.
At each evaluation point, we determined the total number of
patients per group and calculated the median Karnofsky per-
formance status within each group.
Adverse Events
Nephrotoxicity was deﬁned as either a doubling of the
baseline serum creatinine or a concentration of >2 mg/dL.
Hypertension was defined as a change in blood pressure
requiring the start of specific treatment or a treatment
adjustment if the patient was already being treated with an
antihypertensive agent. Hyperglycemia was defined as a
serum glucose level of >140 mg/dL requiring the institution
of diabetic treatment or a dose adjustment of a preexisting
diabetic treatment. Infections were classiﬁed as of unknown
origin when a patient presented with clinical signs of infec-
tion and was treated even though a speciﬁc etiology was not
identified. Other toxicities were evaluated according to
modiﬁed Southwest Oncology Group toxicity criteria.
Statistics
Each patient was categorized as a tacrolimus treatment
success or failure with respect to tacrolimus. Success was
defined as discontinuation of tacrolimus without need for
additional immunosuppression by date of last contact. Fail-
ures were defined as patients who required additional
immunosuppression or a change in the immunosuppressive
regimen resulting in discontinuation of tacrolimus, or death
during tacrolimus treatment. Patients who required
immunosuppression in addition to tacrolimus were further
evaluated, and the ability to be successfully withdrawn from
all immunosuppression was also examined. Survival and dis-
ease-free survival were summarized using the Kaplan-Meier
method. The probabilities of transplantation-related mor-
tality (TRM), successful withdrawal from tacrolimus, and
death during tacrolimus treatment were calculated using
cumulative incidence estimates [29]. Relapse was regarded as
a competing risk for TRM. Death during tacrolimus treat-
ment was regarded as a competing risk for successful with-
drawal of tacrolimus. Successful withdrawal of tacrolimus
was regarded as a competing risk for death during treatment
with tacrolimus. Because some patients, after failing
tacrolimus treatment, stabilized and had immuno-
suppression successfully discontinued at 3 years, this experi-
ence was also described.
Table 2. Characteristics of Patients With Chronic GVHD Enrolled at the Fred
Hutchinson Cancer Research Center Between June 1995 and December 1997*
Type of chronic GVHD
Progressive 8 (20)
Quiescent 24 (60)
De novo 8 (20)
Time from transplantation to chronic GVHD, d
<120 21 (53)
>120 19 (47)
First-line treatment
CSP qod/PDN qod (related BMT donor) 22 (55)
CSP qd/PDN qod (unrelated BMT donor) 13 (32)
CSP/PDN/thalidomide 4 (10)
CSP 1 (3)
Site of chronic GHVD
Skin 37 (92)
Sclerodermatous 9 (22)
Lichenoid 28 (70)
Oral 22 (55)
Liver 17 (43)
Esophagus/gut 10 (25)
Lungs 7 (18)
Eyes 8 (20)
*Data are n (%). GVHD indicates graft-versus-host disease; CSP,
cyclosporine; PDN, prednisone; BMT, bone marrow transplantation.
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RESULTS
Patients
A total of 40 patients were enrolled in the study. The
median time from transplantation to start of therapy with
tacrolimus was 20 months (range, 3-68 months) and from
the diagnosis of chronic GVHD to the start of tacrolimus,
14 months (range, 1-64 months). One patient had leukemic
relapse before the start of the investigational treatment and
was not evaluable for the study purpose.
A total of 22 patients who received transplants from
HLA-matched related donors and 13 patients who received
transplants from HLA-matched unrelated donors were
treated with cyclosporine and prednisone according to Cen-
ter policy. Four other patients were enrolled in an investiga-
tional protocol with cyclosporine/prednisone/thalidomide,
and another patient was treated with only cyclosporine.
Three patients had generalized skin chronic GVHD
alone, and all others had multiorgan involvement (Table 2).
Among the 7 patients with pulmonary involvement, 4 pre-
sented with bronchiolitis obliterans and 3 with a restrictive
pattern more typical of bronchiolitis obliterans with orga-
nizing pneumonia. Ten patients had gastrointestinal
chronic GVHD with diarrhea and/or vomiting. Five had
biopsies of the gastrointestinal tract (all confirming the
presence of GVHD), and 8 had a previous history of acute
enteric GVHD. Of those 10 patients, 5 received a stem cell
graft from an unrelated donor and 3 from a 1-antigen–mis-
matched HLA related donor.
At study entry, the median serum bilirubin was 0.7 mg/dL
(range, 0.3-3.2 mg/dL), the median creatinine was 1.4 mg/dL
(range, 0.3-2.1 mg/dL), the median white blood cell count was
6.53  103/mL (range, 2.1-13.5  103/mL), and the median
platelet count was 174  103/mL (range, 21-410  103/mL).
Of the 35 evaluable patients, 11 had an elevation in the serum
alkaline phosphatase. At 9 to 12 months, 39 patients were
evaluable, and at 18 to 24 and 27 to 36 months, only 38 and
37 patients were evaluable, respectively, because patients were
lost to follow-up at 11 and 19 months. Each patient was
reevaluated in Seattle a median of 2 (range, 0-4) times during
the study period.
Clinical Response
Use of Immunosuppressive Medications for Manage-
ment of Chronic GVHD. Table 3 describes the duration of
treatment with tacrolimus in the study population at different
evaluation points. Thirty-six of 39 patients discontinued
tacrolimus for various reasons at a median time of 9 months
(range, 1-29 months). At 3 years after the start of tacrolimus
treatment, 5 of 39 (13%) evaluable patients discontinued all
immunosuppressive therapy after resolution of chronic
GVHD. Three patients (8%) were clinically stable and main-
tained on immunosuppressive therapy including tacrolimus.
Of the patients, 31 (79%) experienced treatment failure, with
22 patients (56%) requiring a change in immunosuppressive
treatment and 9 patients (23%) dying during treatment with
tacrolimus (Figure 1). Among those patients who experienced
Table 3. Responses to Tacrolimus Treatment Evaluated at Times From the
Start of Tacrolimus Treatment
Evaluation Times
Outcome 9-12 mo 18-24 mo 27-36 mo
Treatment success* 2 6 5
Clinically stable 16 6 3
Treatment failure 21 26 29
Progression 10 13 16
Toxicity 3 4 4
Died during treatment 8 9 9  
with tacrolimus
Total 39 38† 37‡
*Treatment success is defined as alive, in remission, and without
any need for immunosuppression.
†One patient experienced tacrolimus failure and was lost to follow-
up at 11 months.
‡One patient experienced tacrolimus failure and was lost to follow-
up at 19 months.
Figure 1. Time to discontinue tacrolimus. There was a 79% probability of treatment failure or death on tacrolimus treatment (upper curve) and a
13% probability of successful discontinuation of tacrolimus treatment (lower curve). The area between the 2 curves represents the probability of
patients remaining on tacrolimus and being clinically stable at last contact.
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treatment failure and who required a change in immunosup-
pression, 7 patients had the addition of another immunosup-
pressive agent to tacrolimus, and 15 patients discontinued
tacrolimus completely. Eleven patients (28%) discontinued
tacrolimus because of progressive chronic GVHD, and 4
(10%) discontinued because of toxicity. Among the 9 patients
who died between 34 and 539 days (median, 119 days) after
the start of study, 6 had some improvement in their chronic
GVHD before death. In addition to the 5 patients with reso-
lution of chronic GVHD at 3 years, there were 3 additional
patients who discontinued tacrolimus after resolution of
chronic GVHD at the first- and second-year evaluations,
but they all ﬂared later and required additional therapy. At
3 years, the median Karnofsky performance scores for
patients with complete resolution of chronic GVHD, those
with stable disease continuing tacrolimus, and those with
treatment failures were 90 (range, 75-100), 85 (range, 80-90),
and 80 (range, 70-100), respectively.
At 3 years, an additional 2 patients who had failed
tacrolimus and had been considered treatment failures for the
study purpose eventually discontinued all immunosuppres-
sive therapy after resolution of chronic GVHD (Figure 2).
The estimated probability of stopping all immunosuppres-
sion at 3 years after the study start was 29%.
Infections. There were 144 episodes of infection during
tacrolimus treatment. Of those episodes, 42 (29%) were
bacterial, 19 (13%) fungal, and 30 (20%) viral. A total of
53 episodes (37%) were of unknown origin. Lungs were the
most frequently involved site, followed by sinuses and oral
cavity. Bacteremia occurred in 12 patients; among fungal
infections, 4 episodes of Aspergillus were identiﬁed. Varicella
zoster virus and late cytomegalovirus reactivations occurred
in 6 and 3 patients, respectively.
During the study, 13 patients (33%) had between 1 and 3
bacterial infection episodes, 6 (15%) between 1 and 3 fungal
infection episodes, 15 (38%) between 1 and 3 viral episodes,
and 14 (36%) between 1 and 3 infection episodes of
unknown origin. Six patients had no reported infections
during the follow-up period.
Toxicity. Four patients discontinued tacrolimus
because of toxicity. Two patients had progressive renal
deterioration. These 2 patients were changed to another
immunosuppressive agent but died from complications
related to chronic GVHD during the first year after
enrollment in the study. One patient had a major neuro-
logic adverse event related to an accidental overdose of
tacrolimus characterized by general paresthesia and mental
distraction. Another patient had a transient ischemic
attack. Hemolytic uremic syndrome/thrombotic thrombo-
cytopenic purpura was ruled out as a cause. Nonetheless,
the treatment with tacrolimus was discontinued.
The most frequent adverse event not requiring tacrolimus
discontinuation was nephrotoxicity (36%). The severity of
renal toxicity was mild, requiring a dose reduction for a short
interval as the only therapeutic intervention. Other side
effects were nausea (7 of 39, 18%) and neurologic toxicities
(4 of 39, 10%) characterized by tremors, insomnia, and
headache. Hypertension not requiring more than 1 antihy-
pertensive agent occurred in 9 of 39 patients (23%), but only
2 had a new onset of hypertension requiring treatment dur-
ing the study period. Hyperglycemia requiring treatment
occurred in 12 of 39 patients (31%). However, all of them
were also being simultaneously treated with corticosteroids.
One patient was diagnosed with squamous cell carcinoma of
the forearm, which was successfully surgically excised. Avas-
cular necrosis and severe osteoporosis occurred in 20% (8 of
39) and 15% (6 of 39), respectively, of the study population.
Mortality. Overall, 14 of 39 evaluable patients (36%) died
(Table 4). Among those patients, the median time of treat-
ment with tacrolimus was 4 months (range, 2-21 months).
Ten patients died within 12 months of the study start, 3 dur-
ing the second year, and 1 in the third year. At 3 years, the
overall survival was 64% (Figure 3). All 4 patients who
relapsed subsequently died; thus, the disease-free survival at
Figure 2. Time to discontinue immunosuppression. There was a 38% probability of death on any immunosuppression (upper curve) and a 29%
estimated probability of successful discontinuation of any form of immunosuppression at 3 years (lower curve). The area between (33%) represents
the probability of patients remaining on immunosuppression at last contact. The lower curve includes 2 patients in complete remission who were
able to discontinue immunosuppression after failing tacrolimus and the 5 patients who discontinued tacrolimus at 3 years.
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3 years was also 64%. The estimate of transplantation-
related mortality and the probability of relapse at 3 years
were 23% and 10%, respectively. The causes of death are
described in Table 4.
DISCUSSION
Chronic GVHD is the major cause of nonrelapse mor-
tality in long-term survivors after allogeneic stem cell
transplantation [2,5]. The combination of cyclosporine and
prednisone remains the most frequently used first-line
treatment for this complication. Despite this treatment,
the disease often persists, and the overall prognosis for
chronic GVHD requiring salvage therapy is poor [1,3,5,8].
Tacrolimus, thalidomide, and recently, mycophenolate
mofetil have been tested in the treatment of multiorgan
chronic GVHD resistant to cyclosporine and steroids [30-
38]. Since its introduction into the clinical setting, tacro-
limus has been shown to be superior to cyclosporine for
acute GVHD prevention [23-25]. Previous studies have sug-
gested a role for tacrolimus in the treatment of chronic
GVHD resistant to cyclosporine [30,31]. In those studies,
17 and 26 patients were treated, and 6 (35%) and 12 (46%)
had improvement, respectively. However, median follow-up
was short, at only 8 months and 48 days, respectively. The
anatomical sites that showed a higher rate of response were
skin and liver; no responses were achieved in lungs, and only
1 study enrolled patients with gastrointestinal involvement.
Our results confirm that a cohort of patients may
improve after changing from cyclosporine to tacrolimus.
Complete discontinuation of tacrolimus at 3 years without
further changes in immunosuppressive therapy occurred in
5 (13%) patients. Three (8%) patients were improved,
although maintenance with reduced doses of tacrolimus was
required to control chronic GVHD. During the 3 years of
follow-up, an additional 3 patients discontinued immunosup-
pression with tacrolimus but then progressed, requiring fur-
ther immunosuppressive therapy to control chronic GVHD.
Responses were observed in patients with multiorgan involve-
ment, including sclerodermatous skin lesions as well as gas-
trointestinal and pulmonary abnormalities. Compared with
the previous studies of tacrolimus for treatment of refractory
chronic GVHD, our study enrolled a larger proportion of
patients who received a graft from unrelated or mismatched
related donors. The mortality rate reported in our study pop-
ulation is consistent with previous data reported in the litera-
ture and stresses that new investigational approaches require
evaluation to improve outcome [8,32,35].
The most frequent adverse effect was nephrotoxicity,
with an incidence similar to that reported in the other
phase 2 studies [30,31]. At the time of the current study, the
targeted whole blood levels of tacrolimus were 10 to
30 ng/mL. An increased risk of nephrotoxicity with whole
blood levels exceeding 20 ng/mL has been demonstrated in
subsequent studies of acute GVHD prophylaxis [39-41].
Accordingly, lower whole blood levels (10-20 ng/mL) may
reduce the incidence of nephrotoxicity.
Other common side effects of tacrolimus and pred-
nisone therapy included hypertension and hyperglycemia,
which required treatment but did not affect overall
response. Of note in this study population was the high
incidence of bone disease including avascular necrosis
(AVN), osteoporosis, and fractures. Previous studies have
Table 4. Causes of Patient Deaths*
Cause Number of Patients
Infections 7
Bacterial 4
Aspergillus 3
Recurrent malignancy 4
PTLD 1
Other complications 1
Unknown 1
Total 14
*PTLD indicates posttransplantation lymphoproliferative disorders
associated with reactivation of Epstein-Barr virus.
Figure 3. Overall survival. The Kaplan-Meier estimate of the probability of overall survival at 3 years was 64%. The probability of transplantation-
related mortality was 23%.
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shown a strong association of this complication with corti-
costeroid treatment, and a similar incidence rate was
recently reported in a large cohort study of long-term
transplantation survivors [4,42-45]. The impact of AVN on
the quality of life raises concerns about the morbidity of
long-term treatment with corticosteroids and suggests that
steroid-sparing therapies should be investigated in this
patient population.
Vogelsang et al. [32] and Parker et al. [33] reported a
complete response rate of 30% and 11%, respectively, in
2 studies using thalidomide for treatment of refractory or
high-risk chronic GVHD. Complete responses occurred
most often in patients with isolated mouth or liver chronic
GVHD and skin involvement without severe scleroderma.
Patients with gastrointestinal involvement did not have a
high incidence of response. Serious side effects leading to
the discontinuation of thalidomide occurred in 36% of the
patients [32,33]. In a randomized double-blind trial, thalido-
mide or placebo was administered along with cyclosporine
and steroids as initial therapy for chronic GVHD [34]. On
the first, second, and third anniversaries after the start of
treatment, the median performance status score among sur-
viving patients improved from 70% to 90% in both groups.
However, the survival at 3 years after treatment was 49%
and 47% in the treatment and placebo arms, respectively.
Thalidomide and placebo were discontinued in 88% and
65% of patients, respectively, in the 2 groups [34]. In con-
trast, the substitution of tacrolimus for cyclosporine was
well tolerated by patients in the present study.
Deﬁning clinical response in chronic GVHD as well as
acute GVHD sometimes has limitations and may not reﬂect
the actual clinical practice or bedside judgment. These limi-
tations are evident by the many different definitions of
response that investigators of chronic GVHD have given in
their studies [8,30-33,36]. This variability makes compar-
isons of response among the different studies difﬁcult.
Previous studies of acute and chronic GVHD have
shown that the time to treatment failure is a useful and
objective indicator of response to the therapy [34,46]. The
primary parameter considered in this type of assessment is
the clinical status and the requirement for a change in the
therapy administered to the patient evaluated at different
time points. This simple approach improves the reliability
and reproducibility of the response evaluation. Our data con-
ﬁrm that, from this perspective, tacrolimus is well tolerated
and can achieve control of chronic GVHD in a small pro-
portion of patients refractory to cyclosporine/corticosteroids.
REFERENCES
1. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume
KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed.
Boston, MA: Blackwell Science; 1999:515-536.
2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late
deaths after allogeneic bone marrow transplantation: Late Effects
Working Committee of the International Bone Marrow Trans-
plant Registry. N Engl J Med. 1999;341:14-21.
3. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host dis-
ease. In: Ferrara JLM, Deeg HJ, Burakoff S, eds. Graft-versus-Host
Disease. 2nd ed. rev. & expd. New York: Marcel Dekker; 1997:525.
4. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after
marrow transplantation for severe aplastic anemia. Blood. 1998;
91:3637-3645.
5. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in
chronic graft-versus-host disease in patients with aplastic anemia
treated by marrow transplantation from HLA-identical siblings.
Ann Intern Med. 1983;98:461-466.
6. Wagner JL, Flowers MED, Longton G, Storb R, Schubert M,
Sullivan KM. The development of chronic graft-versus-host
disease: an analysis of screening studies and the impact of corti-
costeroid use at 100 days after transplantation. Bone Marrow
Transplant. 1998;22:139-146.
7. Horowitz MM. Uses and growth of hematopoietic cell trans-
plantation. In: Thomas ED, Forman SJ, Blume KG, eds.
Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Black-
well Science; 1999;12-18.
8. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day
cyclosporine and prednisone for treatment of high-risk chronic
graft-versus-host disease. Blood. 1988;72:555-561.
9. Shapiro R. Tacrolimus in solid organ transplantation: an update.
Transplant Proc. 1999;31:2203-2205.
10. Klintmalm GB, Goldstein R, Gonwa T, et al. Use of Prograf
(FK 506) as rescue therapy for refractory rejection after liver
transplantation: US Multicenter FK 506 Liver Study Group.
Transplant Proc. 1993;25:679-688.
11. Mayer AD. Four-year follow-up of the European Tacrolimus
Multicenter Renal Study. Transplant Proc. 1999;31:27S-28S.
12. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus
versus cyclosporine in lung transplantation. Ann Thorac Surg.
1995;60:580-584.
13. Starzl TE, Donner A, Eliasziw M, et al. Randomised trialomania?
The multicentre liver transplant trials of tacrolimus [review].
Lancet. 1995;346:1346-1350.
14. Morris RE, Brown BW Jr. Tacrolimus for prevention of liver allo-
graft rejection: clinical trials and tribulations. Lancet. 1995;
346:1310-1311.
15. European FK506 Multicentre Liver Study Group. Randomised
trial comparing tacrolimus (FK506) and cyclosporin in prevention
of liver allograft rejection. Lancet. 1994;344:423-428.
16. Mayer AD, Dmitrewski J, Squifflet J-P, et al. Multicenter ran-
domized trial comparing tacrolimus (FK506) and cyclosporine in
the prevention of renal allograft rejection: a report of the Euro-
pean Tacrolimus Multicenter Renal Study Group. Transplanta-
tion.1996;64:436-443.
17. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE.
Prevention of graft-versus-host disease following allogeneic bone
marrow transplantation in rats using FK506. Transplantation.
1991;52:590-594.
18. Storb R, Raff RF, Appelbaum FR, et al. FK506 and methotrexate
prevent graft-versus-host disease in dogs given 9.2 Gy total body
irradiation and marrow grafts from unrelated dog leukocyte anti-
gen-nonidentical donors. Transplantation. 1993;56:800-807.
19. Yu C, Storb R, Deeg HJ, et al. Tacrolimus (FK506) and metho-
trexate regimens to prevent graft-versus-host disease after unre-
lated dog leukocyte antigen (DLA) nonidentical marrow trans-
plantation. Bone Marrow Transplant. 1996;17:649-653.
20. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with
methotrexate for the prevention of graft-versus-host disease after
marrow transplantation from matched unrelated donors. Blood.
1996;88:3634-3641.
21. Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus)
monotherapy for prevention of graft-versus-host disease after his-
F. Carnevale-Schianca et al.
620
tocompatible sibling allogeneic bone marrow transplantation.
Blood. 1996;87:3514-3519.
22. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and
minidose methotrexate for prevention of acute graft-versus-host
disease after matched unrelated donor marrow transplantation.
Blood. 1996;88:4383-4389.
23. Nash RA, Antin JH, Karanes C, et al. A phase III study comparing
methotrexate and tacrolimus with methotrexate and cyclosporine
for prophylaxis of acute graft-versus-host disease after marrow
transplantation from unrelated donors. Blood. 2000;96:2062-2068.
24. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III
study comparing methotrexate and tacrolimus (Prograf, FK506)
with methotrexate and cyclosporine for graft-versus-host-disease
prophylaxis after HLA-identical sibling bone marrow transplanta-
tion. Blood. 1998;92:2303-2314.
25. Hiraoka A. Results of a phase III study on prophylactic use of
FK506 for acute GVHD compared with cyclosporin in allogeneic
bone marrow transplantation [abstract]. Blood. 1997;90(suppl
1):561a. Abstract 2500.
26. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients
with acute leukemia treated by chemotherapy, total body irradiation,
and allogeneic marrow transplantation. Blood. 1977; 49:511-533.
27. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclo-
sporine compared with cyclosporine alone for prophylaxis of
acute graft versus host disease after marrow transplantation for
leukemia. N Engl J Med. 1986;314:729-735.
28. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man: a long-term clinicopathologic study
of 20 Seattle patients. Am J Med. 1980;69:204-217.
29. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of
failure probabilities in the presence of competing risks: new repre-
sentations of old estimators [review]. Stat Med. 1999;18:695-706.
30. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK 506 rescue in
chronic graft-versus-host-disease after bone marrow transplanta-
tion. Transplant Proc. 1991;23:3225-3227.
31. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of
graft-versus-host disease developing or exacerbating during pro-
phylaxis and therapy with cyclosporin and/or other immunosup-
pressants: Japanese FK506 BMT Study Group. Bone Marrow
Transplant. 1995;15:885-889.
32. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the
treatment of chronic graft versus host disease. N Engl J Med.
1992;326:1055-1058.
33. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage
therapy for chronic graft-versus-host disease. Blood. 1995;86:
3604-3609.
34. Koc S, Leisenring W, Flowers ME, Sullivan KM, Martin PJ.
Evaluation of thalidomide for the treatment of chronic graft-ver-
sus-host disease in “high risk” patients [abstract]. Blood. 1999;
94(suppl 1):158a. Abstract 693.
35. Nash RA, Furlong T, Storb R, et al. Mycophenolate mofetil
(MMF) as salvage treatment for graft-versus-host-disease
(GVHD) after allogeneic hematopoietic stem cell transplantation
(HSCT): safety analysis [abstract]. Blood. 1997;90(suppl 1):105a.
Abstract 459.
36. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for
the treatment of acute and chronic GVHD in bone marrow trans-
plant patients. Bone Marrow Transplant. 1998;22:61-65.
37. Redei I, Langston AA, Cherry JK, Allen A, Waller EK. Salvage
therapy with mycophenolate mofetil (MMF) for patients with
severe chronic GvHD [abstract]. Blood. 1999;94(suppl 1):159a.
Abstract 698.
38. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for
refractory chronic graft-versus-host disease with mycophenolate
mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-520.
39. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of
tacrolimus (FK506) whole blood concentrations and efﬁcacy and
safety after HLA-identical sibling bone marrow transplantation.
Biol Blood Marrow Transplant. 1998;4:157-163.
40. Woo M, Przepiorka D, Ippoliti C, et al. Toxicities of tacrolimus
and cyclosporin A after allogeneic blood stem cell transplantation
[review]. Bone Marrow Transplant. 1997;20:1095-1098.
41. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of
tacrolimus whole blood levels to efficacy and safety outcomes
after unrelated donor marrow transplantation. Biol Blood Marrow
Transplant. 1999;5:94-97.
42. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone
after allogeneic bone marrow transplantation: analysis of risk fac-
tors for 4388 patients by the Societe Francaise de Greffe de
Moelle (SFGM). Br J Haematol. 1997;97:865-870.
43. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a
common serious complication of allogeneic bone marrow trans-
plantation. Am J Med. 1990;89:733-738.
44. Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS.
Avascular necrosis following bone marrow transplantation: a case-
control study. Bone. 1998;22:67-71.
45. Stern JM, Chesnut CH III, Bruemmer B, et al. Bone density loss
during treatment of chronic GVHD. Bone Marrow Transplant.
1996;17:395-400.
46. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of
therapy for acute graft-versus-host disease: initial treatment.
Blood. 1990;76:1464-1472.
